MARKET

HRTX

HRTX

Heron Therapeutics Inc
NASDAQ
2.050
-0.060
-2.84%
Pre Market: 2.040 -0.01 -0.49% 04:38 05/13 EDT
OPEN
2.150
PREV CLOSE
2.110
HIGH
2.190
LOW
2.040
VOLUME
100
TURNOVER
--
52 WEEK HIGH
3.930
52 WEEK LOW
1.040
MARKET CAP
312.76M
P/E (TTM)
-37.2727
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at HRTX last week (0505-0509)?
Weekly Report · 22h ago
Biotech Outperformance - Can't Take What's Already Earned
Seeking Alpha · 3d ago
Biotech Alert: Searches spiking for these stocks today
TipRanks · 4d ago
Heron Therapeutics: Q1 Paints A Potentially Rosy Picture For 2025
Seeking Alpha · 5d ago
Heron Therapeutics: Strong Q1 Performance and Product Portfolio Growth Reinforce Buy Rating
TipRanks · 5d ago
Heron Therapeutics Reports Strong Q1 2025 Results
TipRanks · 6d ago
Heron Therapeutics Q1 2025 Earnings: Strong Growth Amid Challenges
TipRanks · 6d ago
Heron settles patent dispute with Mylan over antiemetic agents
Seeking Alpha · 6d ago
More
About HRTX
More
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. It creates and commercializes a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. Its acute care product portfolio includes ZYNRELEF and APONVIE. Its oncology care product portfolio includes CINVANTI and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is an intravenous formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for postoperative nausea and vomiting (PONV). CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is an extended-release 5-HT3 receptor antagonist for the prevention of acute and delayed nausea and vomiting.
Recently
Symbol
Price
%Change

Webull offers Heron Therapeutics Inc stock information, including NASDAQ: HRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HRTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HRTX stock methods without spending real money on the virtual paper trading platform.